Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Atalanta Therapeutics has raised $97.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
Atalanta Therapeutics's investors include EQT Life Sciences, Sanofi Ventures, F-Prime, Aberdeen, Pictet Alternative Advisors.
Atalanta Therapeutics is headquartered in Boston, United States.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Atalanta Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atalanta Therapeutics — Funding & Investors." VCBacked, January 28, 2025, https://www.vcbacked.co/company/atalanta-therapeutics. Accessed August 13, 2026.
VCBacked. (2025). Atalanta Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/atalanta-therapeutics
{{cite web |title=Atalanta Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/atalanta-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated